Rhumbline Advisers Atara Biotherapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$0.44 - $1.22 $950 - $2,636	2,161 Added 1.49%	147,574 $101,000
Q4 2023 Feb 08, 2024	SELL	$0.23 - $1.74 $13 - $104	-60 Reduced 0.04%	145,413 $74,000
Q3 2023 Nov 09, 2023	BUY	$1.41 - $2.31 $3,807 - $6,237	2,700 Added 1.89%	145,473 $215,000
Q2 2023 Aug 08, 2023	SELL	$1.5 - $3.04 $6,898 - $13,980	-4,599 Reduced 3.12%	142,773 $229,000
Q1 2023 May 11, 2023	BUY	$2.8 - $5.46 $12,082 - $23,559	4,315 Added 3.02%	147,372 $427,000
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $3,853 - $7,003	1,352 Added 0.95%	143,057 $469,000
Q3 2022 Nov 10, 2022	BUY	$2.85 - $8.73 $7,182 - $21,999	2,520 Added 1.81%	141,705 $536,000
Q2 2022 Aug 11, 2022	BUY	$4.69 - $9.84 $93,007 - $195,137	19,831 Added 16.62%	139,185 $1.08 Million
Q1 2022 May 12, 2022	SELL	$8.44 - $16.89 $73,723 - $147,534	-8,735 Reduced 6.82%	119,354 $1.11 Million
Q4 2021 Feb 10, 2022	BUY	$14.7 - $19.89 $30,164 - $40,814	2,052 Added 1.63%	128,089 $2.02 Million
Q3 2021 Nov 12, 2021	SELL	$11.99 - $17.9 $11,954 - $17,846	-997 Reduced 0.78%	126,037 $2.26 Million
Q2 2021 Aug 05, 2021	BUY	$12.89 - $16.58 $140,513 - $180,738	10,901 Added 9.39%	127,034 $1.98 Million
Q1 2021 May 06, 2021	SELL	$14.0 - $20.72 $89,768 - $132,856	-6,412 Reduced 5.23%	116,133 $1.67 Million
Q4 2020 Feb 10, 2021	BUY	$12.67 - $26.23 $194,877 - $403,443	15,381 Added 14.35%	122,545 $2.41 Million
Q3 2020 Nov 12, 2020	BUY	$11.92 - $15.87 $12,504 - $16,647	1,049 Added 0.99%	107,164 $1.39 Million
Q2 2020 Aug 13, 2020	BUY	$7.53 - $14.93 $243,618 - $483,030	32,353 Added 43.86%	106,115 $1.55 Million
Q1 2020 May 06, 2020	BUY	$5.69 - $17.78 $23,021 - $71,937	4,046 Added 5.8%	73,762 $628,000
Q4 2019 Feb 05, 2020	BUY	$10.89 - $16.79 $17,957 - $27,686	1,649 Added 2.42%	69,716 $1.15 Million
Q3 2019 Oct 23, 2019	BUY	$12.03 - $19.94 $76,173 - $126,260	6,332 Added 10.26%	68,067 $961,000
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $124,587 - $268,401	6,540 Added 11.85%	61,735 $1.24 Million
Q1 2019 May 01, 2019	SELL	$28.4 - $41.74 $31,524 - $46,331	-1,110 Reduced 1.97%	55,195 $2.19 Million
Q4 2018 Jan 31, 2019	BUY	$30.9 - $42.97 $589,015 - $819,094	19,062 Added 51.18%	56,305 $1.96 Million
Q3 2018 Nov 07, 2018	SELL	$35.05 - $43.5 $69,924 - $86,782	-1,995 Reduced 5.08%	37,243 $1.54 Million
Q2 2018 Aug 06, 2018	BUY	$35.15 - $51.45 $199,405 - $291,875	5,673 Added 16.9%	39,238 $1.44 Million
Q1 2018 May 02, 2018	BUY	$18.0 - $48.35 $114,534 - $307,651	6,363 Added 23.39%	33,565 $1.31 Million
Q4 2017 Feb 09, 2018	SELL	$13.2 - $18.1 $58,027 - $79,567	-4,396 Reduced 13.91%	27,202 $492,000
Q3 2017 Nov 06, 2017	BUY	$13.25 - $17.05 $418,673 - $538,745	31,598	31,598 $523,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account